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Abstract
Plasmids are important vectors for the transfer of genetic material among microbes. The 
transfer of plasmids causes transmission of genes involved in pathogenesis and survival, 
to the host bacteria leading to their evolution and adaptation to diverse environmental 
conditions. A large number of plasmids of varying sizes have been discovered and isolated 
from various microorganisms. Plasmids are also valuable tools to genetically manipulate 
microbes for various purposes including production of recombinant proteins. Escherichia 
coli is the most preferred microbe for production of recombinant proteins, due to rapid 
growth rate, cost-effectiveness, high yield of the recombinant proteins and easy scale-up 
process. Several plasmids have been designed to optimize the expression of heterolo-
gous proteins in E. coli. In order to circumvent the issues of protein refolding, the codon 
usage in E. coli, the absence of post-translational modifications, such as glycosylation and 
low recovery of functionally active recombinant proteins, various plasmids have been 
designed and constructed. This chapter summarizes the recent technological advance-
ments that have extended the use of the E. coli expression system to produce more com-
plex proteins, including glycosylated recombinant proteins and therapeutic antibodies.
Keywords: plasmid, recombinant protein, promoter, codon usage, molecular 
chaperones, fusion tags
1. Introduction
Plasmids are defined as extrachromosomal double-stranded circular DNAs within a cell that 
have the capability to replicate independently of chromosomal DNA. Plasmids are found in 
many microorganisms including bacteria, archaea and some eukaryotes such as yeast [1]. 
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The advent of new DNA sequencing technologies has successfully determined the complete 
sequence of 4602 plasmids; most of these plasmids, that is, 4418 are from bacteria, 137 plas-
mids are identified from archaea and 47 plasmids are identified from eukaryotes [2]. The size 
of plasmids can vary between 1 and 200 kb, and they more often harbour genes encoding pro-
teins that confer selective advantage to host cells under adverse conditions. Some of the genes 
are known as resistance genes which confer resistance to certain antibiotics. Genes involved 
in synthesis of antibiotics and various kinds of toxins are also localized on plasmids. Some 
of the genes present on plasmids encode for various virulence factors that assist microbes 
to colonize host and escape from its defence mechanisms. Plasmids also harbour genes that 
empower bacteria to fix nitrogen.
Plasmids can be present in a single bacterial cell in varying number which may range from 
one to few hundreds. The usual number of plasmids that are present in an individual cell is 
termed as copy number and is governed by the size of plasmid and the regulation of rep-
lication initiation. Large-size plasmids are present in low copy number and exist as one or 
very few copies in single bacterium. Such single-copy plasmids employ parABS and parMRC 
systems, termed as partition system, to equally segregate a copy of plasmid to each daughter 
cell upon cell division [3].
Independent replication of plasmids requires the presence of a region of DNA that can serve 
as an origin of replication. A self-replicating unit is termed as a replicon. A classical bacte-
rial replicon comprises of gene for plasmid-specific replication initiation protein (Rep), DnaA 
boxes, AT-rich region and repeating units called iterons [4]. Large-size plasmids also harbour 
genes required for their replication, while smaller plasmids employ host replicative machin-
ery to undergo replication.
Plasmids can be transmitted from one bacteria to another by the process of conjugation, and 
it has been reported that approximately 14% of the currently known plasmids are conjugative 
[5, 6]. Conjugation is a very efficient mechanism to transfer genes among microbes and thus 
facilitate the rapid evolution and adaptation of microbes to various adverse environmental 
conditions [7]. This transfer of genes among bacteria is one mechanism of horizontal gene 
transfer and is responsible for spread of antibiotic resistance among pathogenic microbes [8, 9].
Plasmids are very commonly used as vectors in the field of genetic engineering for the pur-
pose of cloning and expression of desired genes. Various types of plasmids are now available 
commercially for cloning and expression of foreign genes in a wide variety of host including 
E. coli, yeast and mammalian cells [10]. The desired genes to be cloned and expressed are 
inserted into suitable plasmid. For cloning purpose, plasmid vectors are designed to contain 
a site, known as multiple cloning site (MCS) or polylinker site, which allows insertion of 
heterologous genes. The multiple cloning site contains several commonly used restriction 
sites for Type III restriction enzymes. The plasmid vectors contain an origin of replication, 
which allows its replication in bacterial host. Besides, these plasmids also harbour a gene 
that confers resistance to a specific antibiotic such as ampicillin or kanamycin which is used 
as a selectable marker. After the insertion of desired heterologous gene into multiple clon-
ing site of the plasmid vector, the constructed plasmid is introduced into bacterial cells by 
the process of transformation. The transformed cells are further exposed to selective growth 
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medium containing the specific antibiotic. The cells that contain the introduced plasmid will 
be able to survive and grow in selective medium as they carry the plasmid with the antibiotic 
resistance gene. This strategy is employed to clone and express heterologous proteins in E. coli 
for the large-scale production of recombinant proteins for therapeutics and wide variety of 
functional studies [10]. In this chapter, we summarize the recent technological advancements 
in the field of molecular biology that have extended the use of the E. coli expression system 
to produce more complex proteins, including glycosylated recombinant proteins and thera-
peutic antibodies.
2. E. coli as an expression system for production of recombinant 
proteins
Escherichia coli is a very commonly used, robust and cost-effective expression system for large-
scale production of recombinant proteins. E. coli is genetically well characterized and is easy 
to handle and manipulate genetically. Its faster growth rate, inexpensive culture media, high 
expression levels and easy scale-up process provide major advantages for large-scale pro-
duction of recombinant proteins for therapeutic purposes or various functional studies [11]. 
E. coli was successfully used to manufacture recombinant human insulin in 1982 for treating 
diabetes patients. It is important to note that insulin is a heterodimer and entails oxidative 
protein folding to attain a functionally active 3D conformation. The success accomplished 
with high level expression of recombinant human insulin validated the significance of E. coli 
expression system for large-scale production of recombinant proteins. Besides human insu-
lin, several recombinant proteins for therapeutic applications, including human growth 
hormone, interferon α2a and α2b, glucagon, urate oxidase, granulocyte colony-stimulating 
factor and parathyroid hormone, have been successfully manufactured using E. coli expres-
sion system [12]. Although E. coli has been used extensively for expression of heterologous 
proteins, it is still not possible to determine the optimum production conditions for all the 
proteins. Expression conditions that are optimal for one protein may not be ideal for another 
protein. One of the major issues while producing heterologous proteins in E. coli is differ-
ences in codon usage between the two organisms. This difference in codon usage could cause 
errors in translation leading to low expression levels of recombinant proteins [13]. The other 
parameters that can affect the protein expression are choice of promoters, growth conditions 
and hydrophobicity of proteins.
3. Promoter
Promoter is a very critical region in plasmid vectors, used for the expression of heterolo-
gous proteins. Promoter is a stretch of DNA that is involved in the initiation of transcription 
of a gene and is located upstream of the transcription initiation site of gene. Promoters are 
normally 100–1000 base pairs in size. In E. coli and other bacterial species, promoter encom-
passes two short DNA sequences that are 10 nucleotides (termed as the Pribnow Box) and 
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35 nucleotides upstream from the transcription initiation site. The consensus sequence at −10 
region is ‘TATAAT’ and the consensus sequence at −35 region is ‘TTGACA’. This promoter 
sequence is recognized by RNA polymerase which leads to initiation of transcription. Several 
plasmids with strong or weak promoter are now available to express heterologous proteins 
in E. coli. Some of the commonly used promoters in E. coli expression vectors include T7 
promoter, derived from bacteriophage T7, E. coli lac promoter, its improved modified version 
lacUV5 and Tac promoter produced from the combination of trp and lac promoters (Table 1). 
Another important promoter is the trc promoter, which is originated from lacUV5 and trp 
promoters. The potency of a promoter is governed by the frequency of transcription initiation 
which is regulated by the affinity of RNA polymerase for the promoter sequence. The T7 
promoter is very strong as compared to E. coli promoters due to high frequency of transcrip-
tion initiation and efficient processivity and hence it is routinely used for very high expression 
Plasmid Promoter Origin of 
replication
Antibiotic 
selection 
marker
Fusion 
tags
Size of the 
fusion tag
Protease 
cleavage 
site
Vendor
pGEX-2 T tac pBR322 Ampicillin GST 26 kDa Thr Pharmacia
pGEX-3X tac pBR322 Ampicillin GST 26 kDa Xa Pharmacia
pGEX-6P tac pBR322 Ampicillin GST 26 kDa Pre Pharmacia
pMAL-c2X tac ColE1 Ampicillin MBP 42 kDa Xa New England
Biolabs
pMAL-c2E tac ColE1 Ampicillin MBP 42 kDa EK New England
Biolabs
pQE-30/31/32 T5-lac ColE1 Ampicillin N-6XHis 1 kDa None Qiagen
pTrxFus PL ColE1 Ampicillin TRX 11.6 kDa EK Invitrogen
pET-14b T7 pBR322 Ampicillin N-6XHis 1 kDa Thr Novagen
pET-19b T7-lac pBR322 Ampicillin N-6XHis 1 kDa EK Novagen
pET-29a-c(+) T7-lac pBR322 Kanamycin C-6XHis 1 kDa Thr Novagen
pET-41a-c(+) T7-lac pBR322 Kanamycin GST 26 kDa Thr Novagen
pET-43a-c(+) T7-lac pBR322 Kanamycin NusA 55 kDa Thr Novagen
pET-SUMO T7 pBR322 Kanamycin SUMO 11 kDa SUMO
protease
Invitrogen
GST, Glutathione S-transferase; MBP, maltose-binding protein; TRX, thioredoxin; NusA, N-Utilization substance A; 
N-6XHis, N-terminus 6X-histidine; C-6XHis, C-terminus 6X-histidine; SUMO, small ubiquitin-like modifier (SUMO); 
Thr, Thrombin; Xa, Factor Xa; Pre, PreScission; EK, Enterokinase;
Source: http://wolfson.huji.ac.il/expression/bac-strains-prot-exp; http://www.emdmillipore.com/life-science-research/
novagen; http://www.invitrogen.com/1/3/stratagene-products https://www.neb.com
Table 1. List of some commonly used plasmids for improving expression levels and solubility of recombinant proteins 
in E. coli.
Plasmid4
levels of recombinant proteins. However, in some instances, large-scale production of recom-
binant proteins can lead to its accumulation as insoluble aggregates also known as inclusion 
bodies, which can cause poor yield of biologically active recombinant proteins. In such cases, 
the use of expression vector containing a weak promoter such as the trc promoter instead of 
the T7 promoter can enhance protein solubility [14].
4. Ribosomal binding site
Ribosomal binding site is a very crucial component in plasmids commonly used for expres-
sion of recombinant proteins in E. coli. It is comprised of translation initiation codon, that is, 
AUG and the Shine-Dalgarno (SD) sequence and is required for efficient translation initiation 
[15]. Shine-Dalgarno sequence is localized 7–9 nucleotides upstream from the initiation codon 
and the consensus SD sequence is AAGGAGG. Various factors are known to affect translation 
initiation such as secondary structure of ribosomal binding site, consensus SD sequence, vary-
ing number of thymine and adenine and also the nucleotides upstream and downstream of 
the initiation codon AUG [16]. The translation efficiency is enhanced by the presence of more 
number of adenine and thymine in the ribosomal binding site. Highly expressed genes are 
found to contain adenine after the initiation codon [17]. Park and colleagues designed various 
variants of 5′-untranslated region (UTR) comprising of SD sequence and the AU-rich region, 
using PCR-based site-directed mutagenesis and analysed their impact on protein expression 
levels [18]. Such a strategy of modifying 5’UTR could be of immense value to improve trans-
lation efficiency and obtain high expression level of recombinant proteins. Incorporation of 
simple variations in 5’UTR could be exploited to optimize the expression of heterologous 
proteins [18, 19]. Another important factor that could affect the translation efficiency is the 
secondary structures in mRNA which could lead to variations in protein expression levels. 
The RNA helicase DEAD protein of E. coli can be exploited to remove secondary structures in 
mRNA. It had been demonstrated that co-expression of DEAD protein increased the expres-
sion of β-galactosidase from T7 promoter by several fold, implying that DEAD-box protein is 
involved in stabilizing the mRNA [20, 21]. This property of DEAD-box protein can be used to 
enhance the expression of genes which are poorly expressed due to secondary structures of 
mRNA. Protein translation is a highly efficient process as any error during translation could 
cause mutations, misincorporation of amino acids and low expression levels and hence can 
severely affect the quality of recombinant proteins produced in E. coli.
5. Codon usage and plasmid containing tRNA genes cognate to the 
rare codons
Codon usage is a major issue while expressing heterologous proteins, particularly human 
proteins in E. coli. There are marked differences in codon usage between E. coli and humans. 
Codons that are found to be very common in human and other eukaryotic genes are very rare 
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in E. coli. Presence of rare codons in heterologous genes can lead to errors in translation and 
cause low expression levels of recombinant protein in E. coli. The presence of rare codons in 
heterologous genes might cause translational errors due to ribosomal stalling at these posi-
tions. These translational errors include frame-shift mutations, amino acid substitutions or 
premature translation termination [22]. Some of the rare codons in E. coli that cause problems 
in recombinant proteins are AGA, CGG, CGA, AGG (arginine), AAG (lysine), GGA (glycine), 
CUA (leucine), AUA (isoleucine) and CCC (proline) [23]. In E. coli, CGG is a rare arginine 
codon which occurs at a frequency of 0.54%. McNulty and colleagues demonstrated that the 
presence of large number of rare arginine codon CGG in p27 protease domain from Herpes 
Simplex Virus 2 (HSV- 2) resulted in the synthesis of recombinant protein of molecular weight 
that was 3 kDa higher than the actual molecular weight when expressed in E. coli [22]. The 
resultant increase in molecular weight was found to be due to the +1 frame-shift mutation at 
one of the CGG codons at the C-terminus of the viral protein. Besides, glutamine residues 
were misincorporated instead of arginine due to misreading of CGG as CAG [22].
Various strategies have been designed to circumvent the problem of codon bias in E. coli 
for enhancing the production of authentic, biologically active heterologous recombinant 
proteins. One strategy is to synthesize the full-length gene based on codon usage, but the 
high cost of gene synthesis is a major drawback. Another strategy requires site-directed 
mutagenesis of the foreign gene to generate codons which correlates with the tRNA pool of 
E. coli. However, this process is very expensive and time-consuming. Another approach is to 
co-transform the E. coli with plasmid containing the tRNA gene cognate to the rare codons. By 
increasing the copy number of rare tRNA genes, E. coli strains can be designed to complement 
the codon usage frequency in the foreign gene. This strategy is very feasible and cost-effective 
and highly efficient for expression of heterologous genes harbouring large number of rare 
codons. McNulty and colleagues carried out the co-expression of argX gene which codes for 
the cognate tRNA for rare arginine codon CGG, with the p27 protease domain of HSV-2 in 
order to circumvent the problem of codon bias. It was observed that the co-expression of 
cognate tRNA gene for CGG codon resulted in abolition of both frame-shift mutation and 
glutamine misincorporation and enhanced the expression levels of authentic recombinant 
protein by up to sevenfold [22]. This study clearly suggested that supplementation of the 
cognate tRNA for the rare codons such as CGG can alleviate the CGG codon bias in E. coli 
and hence lead to accurate and efficient synthesis of recombinant proteins. This strategy is 
now routinely being employed for several difficult-to-express heterologous recombinant pro-
teins containing rare codons, in E. coli. Currently, several plasmids such as pRARE plasmids 
are commercially available which harbour genes encoding for tRNA cognate to rare codons. 
Another important feature in these pRARE plasmids is the presence of p15A replication ori-
gin, which facilitate their maintenance in the presence of compatible ColE1 origin of replica-
tion, commonly present in several E. coli expression vectors. Moreover, several E. coli strains 
are now commercially available that carry plasmids containing tRNA genes for cognate rare 
codons, such as BL21(DE3) CodonPlus-RIL and Rosetta (DE3). Tegel and colleagues analysed 
the expression of several human proteins in E. coli strain Rosetta (DE3) harbouring pRARE 
plasmid and observed that the total yields of the 35 recombinant proteins out of 68 proteins 
tested were enhanced significantly [24].
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6. Plasmids carrying molecular chaperones for optimization of 
protein folding
Production of recombinant proteins for therapeutic purposes or various functional studies 
requires a robust and cost-effective expression system which can synthesize heterologous pro-
teins in soluble form. Although E. coli expression system is always a preferred choice for expres-
sion of recombinant proteins, accumulation of foreign proteins as insoluble aggregates, also 
called as inclusion bodies, is a major problem. Recovery of proteins from these inclusion bodies is 
a very cumbersome process which entails denaturation and renaturation steps to obtain recom-
binant protein in properly folded and soluble form. However, this extraction process causes tre-
mendous loss of proteins and further reduces the total yield of biologically active recombinant 
proteins. One approach to enhance the solubility of heterologous protein and reduce the forma-
tion of inclusion bodies is to employ molecular chaperones. It is now known that molecular 
chaperones assist the nascent polypeptide to fold properly during the process of protein synthe-
sis and thus prevent protein aggregation. Few molecular chaperones are found to improve fold-
ing and solubilization of misfolded protein, while other chaperones are involved in prevention 
of protein aggregation [25–27]. The commonly used molecular chaperones in E. coli are GroEL, 
GroES, DnaK, DnaJ and Trigger factor (Table 2). These cytoplasmic chaperones can be employed 
either individually or in combination of different chaperones to enhance protein solubility and 
prevent formation of inclusion bodies [10, 26, 28, 29]. The GroEL-GroES chaperone combina-
tion is highly efficient to enhance protein refolding and also prevent protein degradation. It has 
been shown that Trigger factor interacts with GroEL and increases GroEL-substrate binding 
to improve protein folding [30]. Some chaperones such as heat shock proteins IpbA and IpbB 
prevent aggregation of heat denatured proteins [31]. It is advisable to test different combinations 
of molecular chaperones to identify the most efficient combination for improving the solubility 
of heterologous recombinant proteins. Co-expression of molecular chaperones Skp and FkpA 
in E. coli had been shown to improve the solubility of antibody fragments [32]. Combination of 
GroEL-GroES chaperones was found to be very efficient in production of anti-B-type natriuretic 
peptide single-chain antibody (scFv), as 65% of the expressed protein was in soluble form, which 
was almost 2.4-fold more than the one obtained in the absence of chaperones [33].
Plasmid Chaperones Promoter Antibiotic marker Inducer Vendor
pGro7 groES-groEL araB Chloramphenicol L-Arabinose TaKaRa
pKJE7 dnaK-dnaJ-grpE araB Chloramphenicol L-Arabinose TaKaRa
pG-KJE8 dnaK-dnaJ-grpE 
groES-groEL
araB Pzt-1 Chloramphenicol L-Arabinose 
Tetracycline
TaKaRa
pTf16 Trigger factor (tig) araB Chloramphenicol L-Arabinose TaKaRa
pG-Tf2 groES-groEL-tig Pzt-1 Chloramphenicol Tetracycline TaKaRa
pBB540 grpE, clpB Lac Chloramphenicol IPTG Addgene
Table 2. List of plasmids carrying molecular chaperones for improving protein folding in E. coli.
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It has been demonstrated that the periplasm of E. coli presents an ideal environment to express 
complex therapeutic proteins including antibody fragments. The oxidizing condition and Dsb 
protein family in the periplasm provide ideal environment for proper disulphide bond forma-
tion and folding of recombinant proteins. Moreover, very few host proteins are present in the 
periplasm, which leads to high yield of purified recombinant proteins. Therapeutic antibodies 
such as Lucentis and Cimzia (Fab fragments) and few full-length aglycosylated antibodies 
and scFvs have been successfully produced by periplasmic expression in E. coli [34, 35]. Yim 
and colleagues employed the endoxylanase signal peptide to produce large amount of granu-
locyte colony-stimulating factor (GCSF) at 4.2 g/l in the periplasm of E. coli [36]. Co-expression 
of periplasmic chaperones can be exploited to improve the expression of properly folded pro-
tein in periplasm of E. coli. Overexpression of periplasmic chaperones DsbA and DsbC was 
found to enhance the efficiency of the assembly of the heavy chain and light chain of antibody 
in the periplasm of E. coli and drastically increased the production of full-length antibody 
from 0.1 to 1.05 g/l [37]. Co-expression of anti-CD20 scFv antibody with the periplasmic chap-
erone Skp resulted in the enhanced yield as well as antigen binding of antibody [38]. Lee 
and colleagues developed a highly efficient E. coli expression system to produce full-length 
antibody, by modifying 5’UTR sequence and co-expressing periplasmic chaperone DsbC that 
resulted in very high yield of light and heavy chains and improved assembly in the periplasm 
[39]. These successful studies demonstrated that it is possible to produce complex therapeutic 
proteins including therapeutic monoclonal antibodies, through proper engineering of E. coli.
7. Use of plasmids containing fusion tags to improve solubility
Another strategy to improve the solubility of recombinant proteins is to construct a fusion 
with a highly soluble protein. Several plasmid vectors are commercially available that carry 
fusion protein tags. Fusion tags technology can be used to increase protein expression, 
improve solubility as well as facilitate purification of recombinant proteins. Fusion tags are 
currently one of the most preferred methods to produce difficult-to-express heterologous 
proteins in E. coli. Some of the most commonly used fusion tags are maltose-binding protein 
(MBP), glutathione-s-transferase (GST), thioredoxin (TRX), NusA (N-Utilization substance A), 
ubiquitin (Ub), small ubiquitin-like modifier (SUMO) and split SUMO as shown in Table 1 
[40–43]. Marblestone and colleagues carried out a comparative study to evaluate the expres-
sion levels and solubility of three heterologous proteins fused to C-terminus of GST, MBP, 
NusA, Ub, TRX and SUMO fusion tags. TRX and SUMO fusion partners were found to 
enhance the expression levels of recombinant proteins as compared to other fusion tags, while 
SUMO and NusA were found to enhance the solubility of recombinant proteins as compared 
to other fusion tags [41]. Another study by Braun and colleagues analysed the expression of 32 
human proteins of varying molecular weight ranging in size from 17 to 110 kDa using various 
fusion tags and demonstrated that GST and MBP fusion tags are very efficient in improving 
the expression levels and also total yield of recombinant proteins after purification was high 
as compared to other fusion partners [40]. Another study analysed the expression of 40 dif-
ferent heterologous proteins with various fusion tags and observed that MBP fusion tag was 
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very efficient in enhancing the expression levels and solubility of recombinant proteins as 
compared to other fusion tags [44]. The variations in the data from these comparative studies 
suggested that the various fusion tags vary in their efficiency for improving the expression 
and solubility of recombinant proteins, which may depend upon the amino acid composi-
tions, number of disulphide bonds and hydrophobicity of the heterologous proteins. Hence, 
it is advisable to screen for the most efficient fusion tag for each desired heterologous protein 
to improve its expression and solubility. One major issue with using fusion tags for improv-
ing solubility of heterologous protein is the removal of fusion tags, as it may interfere with 
the functional activity of the recombinant proteins. To remove fusion tags, cleavage sites are 
introduced between the fusion tag and recombinant protein, which is recognized and cleaved 
by site-specific proteases such as factor Xa, thrombin protease or SUMO protease. However, 
cleavage of the fusion tags can result in lower yield of recombinant proteins. Hence, it is 
advisable to select the most efficient fusion tag and cleavage strategy to achieve the desirable 
high yield of authentic and biologically active recombinant proteins.
8. Future perspectives
E. coli is a preferred expression system for production of heterologous proteins due to its 
well-characterized genetics, ease of genetic manipulation, availability of several plasmid vec-
tors and engineered host strains, low manufacturing cost, high yield of recombinant proteins 
as compared to other expression systems including yeast, mammalian cell lines, transgenic 
plants and transgenic animals. However, there are some limitations which need to be sur-
mounted such as codon bias, protein folding and solubility issues and post-translational 
modifications. Several technological advancements have been made to address these issues. 
Plasmids such as pRARE plasmids have been designed that contain tRNA genes cognate to 
the rare codons. Co-transformation of these plasmids would increase the copy number of rare 
tRNA genes in E. coli host and thus would be able to complement the codon usage frequency 
in heterologous genes. This strategy is very cost-effective and more efficient for enhancing the 
expression levels of heterologous genes containing large number of rare codons. Solubility 
and proper folding of recombinant proteins can be achieved by using plasmids that contain 
genes encoding for molecular chaperones such as GroEL, GroES, DnaK, DnaJ and Trigger 
factor. Molecular chaperones are known to assist in proper folding of recombinant proteins 
and prevent formation of inclusion bodies. Similarly, fusion protein tags such as GST, MBP, 
NusA, Ub, TRX and SUMO can be exploited to improve the expression levels of difficult-to-
express recombinant proteins and enhance their solubility. In addition, expression of recom-
binant proteins in periplasm of E. coli along with molecular chaperones provides various 
advantages such as improved solubility, proper protein folding, easier protein purification 
and higher yield of authentic and biologically active recombinant proteins. Some of the anti-
bodies that have been approved for therapeutic use in humans such as Lucentis and Cimzia 
have been successfully produced in the periplasm of E. coli, thus confirming the commercial 
viability of this approach. One of the major drawbacks of E. coli expression system is the 
absence of post-translational modifications such as glycosylation which limits its utility for 
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production of complex glycosylated biopharmaceuticals. Wacker and colleagues discovered a 
novel N-linked glycosylation pathway in bacteria Campylobacter jejuni and demonstrated the 
successful transfer of glycosylation pathway in E. coli to generate a strain with capability to 
produce recombinant glycosylated proteins [45]. These various technological advancements 
have demonstrated that E. coli can be engineered specifically for each heterologous protein to 
obtain high yield of biologically active products.
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